Analysts forecast that TransUnion (NYSE:TRU) will announce earnings per share of $0.60 for the current fiscal quarter, according to Zacks. Six analysts have made estimates for TransUnion’s earnings, with the highest EPS estimate coming in at $0.62 and the lowest estimate coming in at $0.59. TransUnion reported earnings per share of $0.47 during the same quarter last year, which would suggest a positive year over year growth rate of 27.7%. The company is scheduled to issue its next quarterly earnings report before the market opens on Tuesday, July 24th.
On average, analysts expect that TransUnion will report full year earnings of $2.42 per share for the current year, with EPS estimates ranging from $2.39 to $2.47. For the next financial year, analysts expect that the business will report earnings of $2.72 per share, with EPS estimates ranging from $2.65 to $2.92. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover TransUnion.
Best Warren Buffett Stocks To Invest In Right Now: Nektar Therapeutics(NKTR)
Nektar Therapeutics, incorporated on June 3, 1998, is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of drug candidates that utilizes its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of molecular entities that targets known mechanisms of action. Its pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives and immunology. The Company's research and development activities involve small molecule drugs, peptides and other biologic drug candidates.
Naloxegol and Naloxegol Fixed-Dose Combination Products (formerly NKTR-118 and NKTR-119), License Agreement with AstraZeneca AB
Naloxegol is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC) which is a common side effect of prescription opioid medications. AstraZeneca has completed a Phase III clinical program for naloxegol AstraZeneca calls the KODIAC studies. The KODIAC studies (KODIAC-04, KODIAC-05, KODIAC-07 and KODIAC-08) naloxegol for treating OIC in patients with non-cancer pain. The KODIAC study includes two 12-week. KODIAC-08 is an open-label, randomized, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and OIC.
Etirinotecan pegol (NKTR-102, next generation, long-acting topoisomerase I inhibitor
The Company is developing etirinotecan pegol (also known as NKTR-102), a next generation topoisomerase I (topo I) inhibitor which was designed using its PEGylation technology. Etirinotecan pegol is a macromolecular chemotherapeutic designed to enhance the anti-cancer effects of topo I inhibition while minimizing its toxicities. Etirinotecan pegol is being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase III open-label, randomized, multicenter clinical study in patients with metastatic ! breast cancer.
BAY41-6551 (Amikacin Inhale, formerly NKTR-061), Agreement with Bayer Healthcare LLC
The Company is developing specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly called NKTR-061) for the treatment of gram negative pneumonias. It is engaged in the third party contract manufacturers to perform its device manufacturing obligations for this program. Bayer initiated enrollment in a global Phase III clinical study, which it calls INHALE, to evaluate the efficacy and safety of Amikacin Inhale versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.
NKTR-181 (mu-opioid analgesic molecule for chronic pain
NKTR-181 is an orally-available mu-opioid drug candidate in development as a long-acting analgesic to treat chronic pain. NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies. NKTR-181 is a mu-opioid analgesic molecule created using Nektar's proprietary polymer conjugate technology, which provides it with a long-acting profile and slows its entry into the CNS. The Company completed two separate Phase I clinical studies of NKTR-181.
NKTR-171 (neuropathic pain
NKTR-171 is an orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain. NKTR-171 is a molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system. NKTR-171 is designed to be a peripherally-restricted molecule which selectively blocks hyper-excitable sodium channels without causing the CNS side effects that limit usage of existing therapies.
NKTR-192 (mu-opioid analgesic molecule for acute pain
NKTR-192 is a mu-opioid analgesic molecule in pr! eclinical! development that is intended to be a short-acting analgesic to treat acute pain. NKTR-192 is also designed to address the abuse liability and serious CNS side effects associated with current opioid therapies. NKTR-192 is also designed to have slow entry into the CNS. The Company is exploring an injectable formulation of NKTR-192 in preclinical development for the treatment of migraine and cancer pain.
NKTR-214 (cytokine immunostimulatory therapy
NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors. NKTR-214 is engineered to selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T cells that dampen the immune response to tumors. The product candidate is in Investigational New Drug application (IND)-enabling studies in preparation for clinical studies in cancer patients.
The Company competes with Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr. Reddy's Laboratories, Ltd., Enzon Pharmaceuticals, Inc., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, Novo Nordisk A/S, Progenics Pharmaceuticals, Inc., Salix Pharmaceuticals, Ltd., Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Mundipharma Int. Limited, Theravance, Inc., Develco Pharma, Sucampo Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited., Acura Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Egalet Ltd, Elite Pharmaceuticals, Inc., Endo Health Solutions Inc., KemPharm, Inc., Pfizer, Inc., Purdue Pharma L.P., and Signature Therapeutics, Inc.
Advisors' Opinion:- [By Keith Speights]
Since analysts' opinions often carry so much weight, which stocks are they most bullish about? Three stocks that Wall Street especially loves right now are Editas Medicine (NASDAQ:EDIT), Nektar Therapeutics (NASDAQ:NKTR), and Viking Therapeutics (NASDAQ:VKTX). Here's why analysts think these three stocks could double your money within the next 12 months.
- [By Motley Fool Transcribing]
Nektar Therapeutics (NASDAQ:NKTR) Q4 2018 Earnings Conference CallFeb. 28, 2019 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Keith Speights]
There are 21 drug stocks in the S&P 500 index, representing the biggest drugmakers in the U.S. The three most profitable companies in this group based on profit margin are Vertex Pharmaceuticals (NASDAQ:VRTX), Nektar Therapeutics (NASDAQ:NKTR), and Regeneron Pharmaceuticals (NASDAQ:REGN). But are these highly profitable drug stocks good picks for investors to buy now?
- [By Demitrios Kalogeropoulos]
Nektar Therapeutics (NASDAQ:NKTR) shareholders trounced the market last month as their stock gained 29% compared to an 8% spike in the S&P 500, according to data provided by S&P Global Market Intelligence.
Best Warren Buffett Stocks To Invest In Right Now: CASI Pharmaceuticals, Inc.(CASI)
CASI Pharmaceuticals, Inc., a biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in North America and China. The company's lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I clinical trial in various different solid tumor cancers, including ovarian, breast, liver, renal, and sarcoma, as well as in leukemia and multiple myeloma; and that has also completed a Phase II clinical trial in advanced ovarian cancer. It also develops late-stage clinical drug candidates, such as ZEVALIN injection for intravenous use; MARQIBO, a microtubule inhibitor for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; and CE Melphalan, a formulation of melphalan. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Repligen (NASDAQ:RGEN) and CASI Pharmaceuticals (NASDAQ:CASI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends. Shares of CASI Pharmaceuticals (NASDAQ:CASI) jumped nearly 32% today after the small-cap pharma announced a new contract drug-manufacturing pact in China. The company now will rely on Yiling Wanzhou International Pharmaceuticals for manufacturing two drugs: entecavir and cilostazol. BidaskClub downgraded shares of CASI Pharmaceuticals (NASDAQ:CASI) from a strong-buy rating to a buy rating in a report released on Saturday morning. Taylor Morrison Home Corporation, incorporated on November 15, 2012, is a real estate development company, with a portfolio of lifestyle and master-planned communities. The Company is engaged in the business of residential homebuilding and the development of lifestyle communities with operations geographically focused in Arizona, California, Colorado, Florida, Texas and its acquired divisions in Georgia, Illinois and North Carolina. The Company operates under the Taylor Morrison and Darling Homes brand names. It also provides financial services to customers through its mortgage subsidiary, Taylor Morrison Home Funding, LLC (TMHF) and title insurance and closing settlement services through its title company, Inspired Title Services, LLC (Inspired Title). The Company's business is organized into over 15 operating divisions aggregated into three homebuilding segments, East, Central and West, and its Mortgage Operations segment, which includes the activities of TMHF and Inspired Title. These segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer service. Homebuilding Operations The Company offers a range of designs through its single-family detached and attached product lines. In addition to move-up products, the Company's portfolio also includes entry-level, luxury and 55 or better products. The Company serves all generational groups through its products and focuses on the needs of homebuyers. It operates as community developers. Community development includes the acquisition and development of communities that may include planning and entitlement approvals and completing construction of off-site and on-site utilities and infrastructure. In some communities, it operates as merchant builders, in which case, it acquires fully planned and entitled lots and may construct on-site improvements but normally do not construct off-site utility or infrastructure improvements. The Company develops a range of communities, which include golf courses, as well as community centers. It also has investments in, and is participants in various joint ventures with related and unrelated parties to develop land and master-planned communities. It develops a number of home designs with features, such as single-story, ranch style living, split bedroom plans and first floor master bedroom suites. The Company's East segment operates in Atlanta, Charlotte, North Florida, Raleigh, and West Florida; Central segment operates in Austin, Dallas, Houston (which includes a Taylor Morrison division and a Darling Homes division); West segment operates in Bay Area, Chicago, Denver, Phoenix, Sacramento, and Southern California. Mortgage Operations TMHF provides a number of mortgage-related services to the Company's customers through its mortgage lending operations. The communities in its homebuilding segments offer single-family attached and detached homes. TMHF operates as a mortgage banker and conducts its business as a Federal Housing Authority (FHA) Full Eagle lender. TMHF funds mortgage loans utilizing warehouse credit line facilities. Get a free copy of the Zacks research report on Taylor Morrison Home (TMHC) For more information about research offerings from Zacks Investment Research, visit Zacks.com Taylor Morrison Home Corp (NYSE:TMHC)Q4 2018 Earnings Conference CallFeb. 13, 2019, 8:30 a.m. ET Operator Taylor Morrison Home Corp (NYSE:TMHC) shares hit a new 52-week low on Wednesday . The stock traded as low as $16.63 and last traded at $16.56, with a volume of 1088619 shares. The stock had previously closed at $16.91. ADDvantage Technologies Group, Inc. distributes and services a line of electronics and hardware products for the cable television and telecommunication industries worldwide. The company's Cable Television segment provides cable television equipment of various original equipment manufacturer suppliers for use in connection with video, telephone, and Internet data signals. It offers headend products, including satellite receivers, integrated receivers/decoders, demodulators, modulators, antennas and antenna mounts, amplifiers, equalizers, and processors for signal acquisition, processing, and manipulation for further transmission; and fiber products, such as optical transmitters, fiber-optic cables, receivers, couplers, splitters, and compatible accessories. This segment also provides access and transport products, such as transmitters, receivers, line extenders, broadband amplifiers, directional taps, and splitters used to permit signals to travel from the headend to their destination in a home, apartment, hotel room, office, or other terminal location; customer premise equipment, including digital converter and modem boxes to receive, record, and transmit video, data, and telephony signals; test equipment for use in the set-up, signal testing, and maintenance of electronic equipment, as well as support of cable television plant; and hardware equipment, such as connector and cable products. Its Telecommunications segment offers used telecommunication equipment, such as component parts, as well as spares or replace non-working components. This segment provides central office equipment, including optical, switching, and data equipment on a customer's communication network. It also provides equipment repair services to cable operators. The company was formerly known as ADDvantage Media Group, Inc. and changed its name to ADDvantage Technologies Group, Inc. in December 1999. The company was founded in 1989 and is headquartered in Broken Arrow, Oklahoma. Media coverage about ADDvantage Technologies Group (NASDAQ:AEY) has trended positive on Saturday, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ADDvantage Technologies Group earned a media sentiment score of 0.47 on Accern’s scale. Accern also assigned media coverage about the technology company an impact score of 47.0561890892472 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days. Harmonic Inc. designs, manufactures, and sells video infrastructure products and system solutions to create, prepare, and deliver a range of video services for television and media platforms in the united States and internationally. Its products include video production platforms and playout solutions, such as video servers used by broadcasters, content owners, and multi-channel network operators to create and play-to-air television channels; video-optimized storage, which provides storage capacity and access bandwidth to support media production applications comprising video editing, content transformation, and media library management; and media applications that provide media integrated management and workflow control over content stored on its systems. The company offers video processing products, including broadcast encoders; contribution and distribution encoders; stream processing and statistical multiplexing solutions; content preparation and delivery for multi-scr een applications; decoders and descramblers; and management and control software. It also provides edge products that integrate routing, multiplexing, scrambling, and modulation into a single package; optical transmitters and amplifiers, which operates at various optical wavelengths and serves long-haul and local transport applications in the cable distribution network; optical nodes to supports network architectures for bandwidth delivered to a service area; and return path transmitters that support two-way transmission capabilities for analog or digital transport. In addition, the company offers technical support and professional services, such as maintenance and support; and consulting, implementation, and integration services. Harmonic Inc. sells its products through direct sales force, independent distributors, and integrators to cable, satellite and telco, and broadcast and media companies. The company was founded in 1988 and is headquartered in San Jose, California. Advisors' Opinion: Harmonic Inc (NASDAQ:HLIT)Q1 2019 Earnings CallApril 29, 2019, 5:00 p.m. ET Operator Harmonic Inc. (NASDAQ: HLIT) was started as Buy with a $7 target price (versus a $5.32 close) at Needham. NetApp Inc. (NASDAQ: NTAP) was last seen down 8.5% at $61.60, based on its guidance after earnings. William Blair downgraded it to Market Perform from Outperform. JPMorgan also downgraded NetApp, to Neutral from Overweight. Harmonic Inc (NASDAQ:HLIT)Q4 2018 Earnings Conference CallFeb. 04, 2019, 5:00 p.m. ET Operator Harmonic (NASDAQ:HLIT) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Thursday.Best Warren Buffett Stocks To Invest In Right Now: Taylor Morrison Home Corporation(TMHC)
Best Warren Buffett Stocks To Invest In Right Now: ADDvantage Technologies Group, Inc.(AEY)
Best Warren Buffett Stocks To Invest In Right Now: Harmonic Inc.(HLIT)
No comments:
Post a Comment